VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q57306348 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241120235738.0
008 241120nneanz||abbn n and d
035 ‎‡a (WKP)Q57306348‏
024 ‎‡a 0000-0002-3097-2834‏ ‎‡2 orcid‏
024 ‎‡a 57203815908‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q57306348‏
100 0 ‎‡a Francesco Costa‏ ‎‡c researcher (ORCID 0000-0002-3097-2834)‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Francesco Costa‏ ‎‡c onderzoeker‏ ‎‡9 nl‏
670 ‎‡a Author's 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS‏
670 ‎‡a Author's Actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboración con la EACTS‏
670 ‎‡a Author's Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions‏
670 ‎‡a Author's Benefit of radial approach in reducing the incidence of acute kidney injury after percutaneous coronary intervention: A meta-analysis of 22,108 patients‏
670 ‎‡a Author's Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach?‏
670 ‎‡a Author's Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease‏
670 ‎‡a Author's Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk: navigating between limited evidence and clinical concerns‏
670 ‎‡a Author's Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial‏
670 ‎‡a Author's Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey‏
670 ‎‡a Author's Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?‏
670 ‎‡a Author's Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities.‏
670 ‎‡a Author's Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment‏
670 ‎‡a Author's Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis.‏
670 ‎‡a Author's Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.‏
670 ‎‡a Author's Impact of vascular access on acute kidney injury after percutaneous coronary intervention.‏
670 ‎‡a Author's Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY t‏
670 ‎‡a Author's Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy‏
670 ‎‡a Author's Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial‏
670 ‎‡a Author's Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration‏
670 ‎‡a Author's Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials‏
670 ‎‡a Author's Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction‏
670 ‎‡a Author's Myocardial ischemia due to a recanalized chronic coronary thrombus: Angiographic and optical coherence tomography imaging insights‏
670 ‎‡a Author's Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials‏
670 ‎‡a Author's Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization: Fifty Years of Revascularization: Where Are We and Where Are We Heading?‏
670 ‎‡a Author's Radial Artery Access for Percutaneous Cardiovascular Interventions: Contemporary Insights and Novel Approaches‏
670 ‎‡a Author's Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer‏
670 ‎‡a Author's The Rotterdam Radial Access Research‏
670 ‎‡a Author's "Ticagrelor or Prasugrel, Doctor?" The Basis for Decision in Clinical Practice‏
909 ‎‡a (orcid) 0000000230972834‏ ‎‡9 1‏
909 ‎‡a (scopus) 57203815908‏ ‎‡9 1‏
912 ‎‡a 2017escfocusedupdateondualantiplatelettherapyincoronaryarterydiseasedevelopedincollaborationwitheacts‏ ‎‡A 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS‏ ‎‡9 1‏
912 ‎‡a actualizacionesc2017sobreeltratamientoantiagreganteplaquetariodobleenlaenfermedadcoronariadesarrolladaencolaboracionconlaeacts‏ ‎‡A Actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboración con la EACTS‏ ‎‡9 1‏
919 ‎‡a optimaldurationofdualantiplatelettherapyafterpercutaneouscoronaryinterventionwithdrugelutingstentsmetaanalysisofrandomisedcontrolledtrials‏ ‎‡A Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials‏ ‎‡9 1‏
919 ‎‡a perspectivesonthe2014esceactsguidelinesonmyocardialrevascularizationfiftyyearsofrevascularizationwhereareweandwhereareweheading‏ ‎‡A Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization: Fifty Years of Revascularization: Where Are We and Where Are We Heading?‏ ‎‡9 1‏
919 ‎‡a radialarteryaccessforpercutaneouscardiovascularinterventionscontemporaryinsightsandnovelapproaches‏ ‎‡A Radial Artery Access for Percutaneous Cardiovascular Interventions: Contemporary Insights and Novel Approaches‏ ‎‡9 1‏
919 ‎‡a roleofstenttypeandofdurationofdualantiplatelettherapyinpatientswithchronickidneydiseaseundergoingpercutaneouscoronaryinterventionsisbaremetalstentimplantationstillajustifiablechoiceaposthocanalysisoftheallcomer‏ ‎‡A Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer‏ ‎‡9 1‏
919 ‎‡a rotterdamradialaccessresearch‏ ‎‡A The Rotterdam Radial Access Research‏ ‎‡9 1‏
919 ‎‡a ticagrelororprasugreldoctorthebasisfordecisioninclinicalpractice‏ ‎‡A "Ticagrelor or Prasugrel, Doctor?" The Basis for Decision in Clinical Practice‏ ‎‡9 1‏
919 ‎‡a antithrombotictherapyforpercutaneouscardiovascularinterventionsfromcoronaryarterydiseasetostructuralheartinterventions‏ ‎‡A Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions‏ ‎‡9 1‏
919 ‎‡a benefitofradialapproachinreducingtheincidenceofacutekidneyinjuryafterpercutaneouscoronaryinterventionametaanalysisof22108patients‏ ‎‡A Benefit of radial approach in reducing the incidence of acute kidney injury after percutaneous coronary intervention: A meta-analysis of 22,108 patients‏ ‎‡9 1‏
919 ‎‡a bleedingriskstratificationinacutecoronarysyndromesisitstillvalidintheeraoftheradialapproach‏ ‎‡A Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach?‏ ‎‡9 1‏
919 ‎‡a casebasedimplementationofthe2017escfocusedupdateondualantiplatelettherapyincoronaryarterydisease‏ ‎‡A Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease‏ ‎‡9 1‏
919 ‎‡a coronarystentselectionandoptimalcourseofdualantiplatelettherapyinpatientsathighbleedingorthromboticrisknavigatingbetweenlimitedevidenceandclinicalconcerns‏ ‎‡A Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk: navigating between limited evidence and clinical concerns‏ ‎‡9 1‏
919 ‎‡a doessmokinghabitaffecttherandomizedcomparisonof6versus24monthdualantiplatelettherapydurationinsightsfromtheprodigytrial‏ ‎‡A Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial‏ ‎‡9 1‏
919 ‎‡a dualantiplatelettherapydurationaftercoronarystentinginclinicalpracticeresultsofaneapcisurvey‏ ‎‡A Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey‏ ‎‡9 1‏
919 ‎‡a durationofdualantiplatelettherapyafterdrugelutingstentimplantationwillweeverreachaconsensus‏ ‎‡A Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?‏ ‎‡9 1‏
919 ‎‡a impactofclinicalpresentationondualantiplatelettherapydurationletsreevaluateourpriorities‏ ‎‡A Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities.‏ ‎‡9 1‏
919 ‎‡a impactofclinicalpresentationonischaemicandbleedingoutcomesinpatientsreceiving6or24monthdurationofdualantiplatelettherapyafterstentimplantationaprespecifiedanalysisfromtheprodigyprolongingdualantiplatelettreatment‏ ‎‡A Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment‏ ‎‡9 1‏
919 ‎‡a impactofgreaterthan12monthdualantiplatelettherapydurationonmortalitydrugspecificoraclasseffectametaanalysis‏ ‎‡A Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis.‏ ‎‡9 1‏
919 ‎‡a impactofprotonpumpinhibitorsonclinicaloutcomesinpatientstreatedwitha6or24monthdualantiplatelettherapydurationinsightsfromtheprolongingdualantiplatelettreatmentaftergradingstentinducedintimalhyperplasiastudytrial‏ ‎‡A Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.‏ ‎‡9 1‏
919 ‎‡a impactofvascularaccessonacutekidneyinjuryafterpercutaneouscoronaryintervention‏ ‎‡A Impact of vascular access on acute kidney injury after percutaneous coronary intervention.‏ ‎‡9 1‏
919 ‎‡a incidenceprognosticimpactandoptimaldefinitionofcontrastinducedacutekidneyinjuryinconsecutivepatientswithstableorunstablecoronaryarterydiseaseundergoingpercutaneouscoronaryinterventioninsightsfromtheallcomerprodigyt‏ ‎‡A Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY t‏ ‎‡9 1‏
919 ‎‡a incrementalvalueofthecrusadeacuityandhasbledriskscoresforthepredictionofhemorrhagiceventsaftercoronarystentimplantationinpatientsundergoinglongorshortdurationofdualantiplatelettherapy‏ ‎‡A Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy‏ ‎‡9 1‏
919 ‎‡a isbaremetalstentimplantationstilljustifiableinhighbleedingriskpatientsundergoingpercutaneouscoronaryinterventionaprespecifiedanalysisfromthezeustrial‏ ‎‡A Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial‏ ‎‡9 1‏
919 ‎‡a leftmainorproximalleftanteriordescendingcoronaryarterydiseaselocationidentifieshighriskpatientsderivingpotentiallygreaterbenefitfromprolongeddualantiplatelettherapyduration‏ ‎‡A Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration‏ ‎‡9 1‏
919 ‎‡a longtermdualantiplatelettherapyforsecondarypreventionofcardiovasculareventsinthesubgroupofpatientswithpreviousmyocardialinfarctionacollaborativemetaanalysisofrandomizedtrials‏ ‎‡A Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials‏ ‎‡9 1‏
919 ‎‡a longtermuseofticagrelorinpatientswithpriormyocardialinfarction‏ ‎‡A Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction‏ ‎‡9 1‏
919 ‎‡a myocardialischemiaduetoarecanalizedchroniccoronarythrombusangiographicandopticalcoherencetomographyimaginginsights‏ ‎‡A Myocardial ischemia due to a recanalized chronic coronary thrombus: Angiographic and optical coherence tomography imaging insights‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000408296109‏
996 ‎‡2 BLBNB|000433691‏
996 ‎‡2 ISNI|0000000067439561‏
996 ‎‡2 DNB|12200082X‏
996 ‎‡2 ISNI|0000000114446271‏
996 ‎‡2 VLACC|000000617‏
996 ‎‡2 PTBNP|1406339‏
996 ‎‡2 LC|n 84231072‏
996 ‎‡2 ISNI|0000000068210371‏
996 ‎‡2 BLBNB|001583997‏
996 ‎‡2 LC|n 82040083‏
996 ‎‡2 BNF|14576978‏
996 ‎‡2 DNB|103849483‏
996 ‎‡2 DNB|123281024‏
996 ‎‡2 PTBNP|181865‏
996 ‎‡2 PLWABN|9810621032205606‏
996 ‎‡2 PTBNP|225699‏
996 ‎‡2 LC|no2016093031‏
996 ‎‡2 ISNI|0000000068904840‏
996 ‎‡2 ISNI|0000000118851688‏
996 ‎‡2 SUDOC|168592843‏
996 ‎‡2 ISNI|0000000394656977‏
996 ‎‡2 ISNI|0000000002274954‏
996 ‎‡2 ISNI|0000000077960019‏
996 ‎‡2 ICCU|CFIV247346‏
996 ‎‡2 PTBNP|225032‏
996 ‎‡2 ISNI|000000007021905X‏
996 ‎‡2 PTBNP|52190‏
996 ‎‡2 LC|n 94013455‏
996 ‎‡2 PTBNP|1389331‏
996 ‎‡2 ISNI|0000000068889812‏
996 ‎‡2 DNB|170808793‏
996 ‎‡2 J9U|987007267051905171‏
996 ‎‡2 SUDOC|168089475‏
996 ‎‡2 PTBNP|52031‏
996 ‎‡2 PTBNP|52032‏
996 ‎‡2 LC|no2020139228‏
996 ‎‡2 SUDOC|07364451X‏
996 ‎‡2 NII|DA19018238‏
996 ‎‡2 ISNI|0000000067996819‏
996 ‎‡2 DNB|1265427321‏
996 ‎‡2 ISNI|0000000434631003‏
996 ‎‡2 ISNI|0000000039391062‏
996 ‎‡2 LC|nr2003009987‏
996 ‎‡2 SUDOC|132955709‏
996 ‎‡2 ISNI|0000000069420557‏
996 ‎‡2 LC|n 84116278‏
996 ‎‡2 SUDOC|028369122‏
996 ‎‡2 NSK|000028029‏
996 ‎‡2 PTBNP|10409‏
996 ‎‡2 ICCU|PUVV463196‏
996 ‎‡2 SUDOC|091537215‏
996 ‎‡2 DNB|116689080‏
996 ‎‡2 J9U|987007343448405171‏
996 ‎‡2 PTBNP|72394‏
996 ‎‡2 ISNI|0000000082368917‏
996 ‎‡2 DNB|1158790902‏
996 ‎‡2 PTBNP|52089‏
996 ‎‡2 NTA|088865207‏
996 ‎‡2 BNE|XX1234213‏
996 ‎‡2 ISNI|0000000373445003‏
996 ‎‡2 CAOONL|ncf11744840‏
996 ‎‡2 ICCU|CUBV048723‏
996 ‎‡2 BLBNB|000166757‏
996 ‎‡2 SUDOC|067693741‏
996 ‎‡2 BNE|XX6051796‏
996 ‎‡2 NII|DA10584112‏
996 ‎‡2 ISNI|0000000069815508‏
996 ‎‡2 PTBNP|30301‏
996 ‎‡2 LC|no 99077152‏
996 ‎‡2 PTBNP|193125‏
996 ‎‡2 LC|n 91029679‏
996 ‎‡2 DNB|116340201X‏
996 ‎‡2 CAOONL|ncf10147071‏
996 ‎‡2 NTA|165711000‏
996 ‎‡2 NUKAT|n 2008088135‏
996 ‎‡2 ISNI|000000045490403X‏
996 ‎‡2 LC|n 2018250297‏
996 ‎‡2 ISNI|0000000069080169‏
996 ‎‡2 LC|n 2009046510‏
996 ‎‡2 SUDOC|087153807‏
996 ‎‡2 DE633|pe30086806‏
996 ‎‡2 ISNI|0000000024463430‏
996 ‎‡2 DNB|138039550‏
996 ‎‡2 BLBNB|000167595‏
996 ‎‡2 DNB|116306912‏
996 ‎‡2 LC|n 97115238‏
996 ‎‡2 LC|n 2023252897‏
996 ‎‡2 BNC|981058510882106706‏
996 ‎‡2 ISNI|0000000080003383‏
996 ‎‡2 BNCHL|10000000000000000182591‏
996 ‎‡2 DNB|170069761‏
996 ‎‡2 BAV|495_88353‏
996 ‎‡2 BAV|495_88359‏
996 ‎‡2 PTBNP|270467‏
996 ‎‡2 NUKAT|n 2017034896‏
996 ‎‡2 ISNI|0000000034194326‏
996 ‎‡2 LC|nb2023009141‏
996 ‎‡2 LC|n 87107030‏
996 ‎‡2 NII|DA17441496‏
996 ‎‡2 ISNI|0000000070014775‏
996 ‎‡2 J9U|987007447201805171‏
996 ‎‡2 PTBNP|166681‏
996 ‎‡2 RERO|A011068211‏
996 ‎‡2 SUDOC|070832781‏
996 ‎‡2 SUDOC|252982983‏
996 ‎‡2 JPG|500199645‏
996 ‎‡2 SUDOC|18579100X‏
996 ‎‡2 BAV|495_88594‏
996 ‎‡2 PTBNP|41641‏
996 ‎‡2 LC|no2011118591‏
996 ‎‡2 PTBNP|1452749‏
996 ‎‡2 PTBNP|217432‏
996 ‎‡2 PTBNP|151694‏
996 ‎‡2 PTBNP|125782‏
996 ‎‡2 BLBNB|000466708‏
996 ‎‡2 PTBNP|52107‏
996 ‎‡2 DNB|1052730086‏
996 ‎‡2 PTBNP|196623‏
996 ‎‡2 PTBNP|237903‏
996 ‎‡2 DNB|115845968‏
996 ‎‡2 ISNI|0000000370077436‏
996 ‎‡2 SUDOC|245177671‏
996 ‎‡2 PTBNP|183593‏
996 ‎‡2 PTBNP|1469757‏
996 ‎‡2 ISNI|0000000038344926‏
996 ‎‡2 BLBNB|000167625‏
996 ‎‡2 DNB|133874729‏
996 ‎‡2 BNF|14853841‏
996 ‎‡2 DNB|1057249998‏
996 ‎‡2 DNB|1056407271‏
996 ‎‡2 RERO|A003138016‏
996 ‎‡2 RERO|A003138014‏
996 ‎‡2 BNF|16229154‏
996 ‎‡2 SUDOC|084744693‏
996 ‎‡2 RERO|A003138018‏
996 ‎‡2 ISNI|0000000069014188‏
996 ‎‡2 BNF|16276873‏
996 ‎‡2 BNE|XX5711618‏
996 ‎‡2 SUDOC|163775443‏
996 ‎‡2 ICCU|CFIV002315‏
996 ‎‡2 PTBNP|164429‏
996 ‎‡2 SUDOC|026800535‏
996 ‎‡2 ISNI|0000000110266468‏
996 ‎‡2 ISNI|0000000078255485‏
996 ‎‡2 ICCU|BVEV175886‏
996 ‎‡2 ISNI|0000000069816965‏
996 ‎‡2 DNB|133410609‏
996 ‎‡2 ISNI|0000000031467923‏
996 ‎‡2 ISNI|0000000067970766‏
996 ‎‡2 DNB|1157294952‏
996 ‎‡2 PTBNP|121410‏
996 ‎‡2 DNB|120429710X‏
996 ‎‡2 SUDOC|101683359‏
996 ‎‡2 PTBNP|217334‏
996 ‎‡2 ISNI|0000000355917468‏
996 ‎‡2 PTBNP|181973‏
996 ‎‡2 ISNI|0000000068815952‏
996 ‎‡2 BNF|13933178‏
996 ‎‡2 ISNI|0000000066467958‏
996 ‎‡2 ISNI|0000000382549904‏
996 ‎‡2 PTBNP|227816‏
996 ‎‡2 NTA|118819380‏
996 ‎‡2 BLBNB|000631669‏
996 ‎‡2 PLWABN|9810563248405606‏
996 ‎‡2 ISNI|0000000082850930‏
996 ‎‡2 ISNI|0000000067567010‏
996 ‎‡2 NTA|22636612X‏
996 ‎‡2 LC|nb2015006295‏
996 ‎‡2 LC|n 2005177878‏
996 ‎‡2 BNE|XX1188976‏
996 ‎‡2 BLBNB|001033234‏
996 ‎‡2 ISNI|0000000114696860‏
996 ‎‡2 LC|no2020003608‏
996 ‎‡2 RERO|A016313963‏
996 ‎‡2 NTA|069677107‏
996 ‎‡2 ISNI|0000000373530857‏
996 ‎‡2 PTBNP|142475‏
996 ‎‡2 J9U|987007295099805171‏
996 ‎‡2 NUKAT|n 2009146564‏
996 ‎‡2 BLBNB|000563112‏
996 ‎‡2 ISNI|0000000059428459‏
996 ‎‡2 LC|n 2017251313‏
996 ‎‡2 PTBNP|115506‏
996 ‎‡2 PTBNP|1397931‏
996 ‎‡2 PTBNP|225669‏
996 ‎‡2 DNB|133911500‏
996 ‎‡2 ISNI|0000000069293113‏
996 ‎‡2 BLBNB|000532439‏
996 ‎‡2 JPG|500590574‏
996 ‎‡2 LC|n 2007209907‏
996 ‎‡2 J9U|987007386754505171‏
996 ‎‡2 BNF|12021854‏
996 ‎‡2 SUDOC|068667612‏
996 ‎‡2 J9U|987007435263905171‏
996 ‎‡2 LC|nr 94013377‏
996 ‎‡2 LC|n 79034288‏
996 ‎‡2 BNF|17805471‏
996 ‎‡2 LC|no2008148707‏
996 ‎‡2 ISNI|0000000051284948‏
996 ‎‡2 BLBNB|000424232‏
996 ‎‡2 PTBNP|1796315‏
996 ‎‡2 J9U|987011050563105171‏
996 ‎‡2 PTBNP|1875355‏
996 ‎‡2 ISNI|0000000067746561‏
996 ‎‡2 ISNI|0000000449655139‏
996 ‎‡2 PTBNP|244185‏
996 ‎‡2 LC|nr2002005690‏
996 ‎‡2 RERO|A027286371‏
996 ‎‡2 ISNI|0000000118885781‏
996 ‎‡2 ISNI|0000000047909781‏
996 ‎‡2 ISNI|000000037353572X‏
996 ‎‡2 NUKAT|n 2014181682‏
996 ‎‡2 ISNI|0000000070826167‏
996 ‎‡2 DNB|122602226‏
996 ‎‡2 NTA|095236929‏
996 ‎‡2 LC|ns2015003965‏
996 ‎‡2 ISNI|0000000066660029‏
996 ‎‡2 LC|no2021042427‏
996 ‎‡2 PTBNP|53249‏
996 ‎‡2 DNB|172034515‏
996 ‎‡2 ISNI|0000000047823785‏
996 ‎‡2 ISNI|0000000067152130‏
996 ‎‡2 ISNI|0000000022228840‏
996 ‎‡2 DNB|1048528812‏
996 ‎‡2 BIBSYS|90278985‏
996 ‎‡2 BLBNB|000362165‏
996 ‎‡2 DE633|pe30010686‏
996 ‎‡2 CAOONL|ncf10128808‏
996 ‎‡2 BLBNB|001286239‏
996 ‎‡2 SUDOC|185975879‏
996 ‎‡2 LC|n 2006210827‏
996 ‎‡2 LC|n 2015210947‏
996 ‎‡2 LC|no2018109604‏
996 ‎‡2 BLBNB|001423947‏
996 ‎‡2 SUDOC|06720581X‏
996 ‎‡2 PTBNP|266286‏
996 ‎‡2 DNB|1135227187‏
996 ‎‡2 ICCU|CFIV199681‏
996 ‎‡2 PTBNP|220340‏
996 ‎‡2 ISNI|0000000027530301‏
996 ‎‡2 LC|n 86100408‏
996 ‎‡2 BLBNB|000503070‏
996 ‎‡2 PTBNP|199643‏
996 ‎‡2 DNB|1024924424‏
996 ‎‡2 SUDOC|077728807‏
996 ‎‡2 ISNI|0000000069413058‏
996 ‎‡2 RERO|A008959656‏
996 ‎‡2 ARBABN|000048028‏
996 ‎‡2 SUDOC|242609937‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏